A phase 1/2 study of autologous neuroblastoma tumor cells genetically modified to secrete il-2 in patients with high-risk neuroblastoma

Journal of Immunotherapy

Volumn 31, Issue 9, 2008, Pages 812-819

  Russell, Heidi V ^a   Strother, Douglas ^a   Mei, Zhuyong ^a   Rill, Donna ^b   Popek, Edwina ^b   Biagi, Ettore ^c   Yvon, Eric ^c   Brenner, Malcolm ^c   Rousseau, Raphael ^c  

^a TEXAS CHILDREN S CANCER CENTER   (United States)

^b Center for Cell and Gene Therapy   (United States)

^c CENTRE LÉON BÉRARD   (France)

Author keywords

Gene therapy; Neuroblastoma; Vaccine

Indexed keywords

CYTOKINE; INTERLEUKIN 2;

ARTICLE; BONE TUMOR; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHILD; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; GENE THERAPY; GENETIC TRANSDUCTION; GENETICS; HUMAN; IMMUNOLOGY; IMMUNOPHENOTYPING; LYMPHOCYTE ACTIVATION; MALE; METABOLISM; MORTALITY; NEUROBLASTOMA; PATHOLOGY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRESCHOOL CHILD; SECRETION; SOFT TISSUE TUMOR; SUBCUTANEOUS DRUG ADMINISTRATION; SURVIVAL;

BONE NEOPLASMS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CHILD; CHILD, PRESCHOOL; CYTOKINES; FEMALE; GENE THERAPY; HUMANS; IMMUNOPHENOTYPING; INJECTIONS, SUBCUTANEOUS; INTERLEUKIN-2; LYMPHOCYTE ACTIVATION; MALE; NEUROBLASTOMA; SOFT TISSUE NEOPLASMS; SURVIVAL ANALYSIS; TOMOGRAPHY, X-RAY COMPUTED; TRANSDUCTION, GENETIC;

EID: 67650165136     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/CJI.0b013e3181869893     Document Type: Article

References (26)

1. Hege KM, Jooss K, Pardoll D. GM-CSF gene-modified cancer cell immunotherapies: of mice and men. Int Rev Immunol. 2006;25:321-352.
2. Dilloo D, Bacon K, Holden W, et al. Combined chemokine and cytokine gene transfer enhances antitumor immunity. Nat Med. 1996;2:1090-1095.
3. Bowman L, Grossmann M, Rill D, et al. IL-2 adenovector-transduced autologous tumor cells induce antitumor immune responses in patients with neuroblastoma. Blood. 1998;92:1941-1949.
4. Yu JS, Wei MX, Chiocca EA, et al. Treatment of glioma by engineered interleukin 4-secreting cells. Cancer Res. 1993;53:3125-3128.
5. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med. 2004;10:909-915.
6. Brodeur GM, Pritchard J, Berthold F, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol. 1993;11:1466-1477.
7. Bowman LC, Grossmann M, Rill D, et al. Interleukin-2 gene-modified allogeneic tumor cells for treatment of relapsed neuroblastoma. Hum Gene Ther. 1998;9:1303-1311.
8. + T-cell regenerative pathways result in prolonged T-cell subset imbalance after intensive chemotherapy. Blood. 1997;89:3700-3707.
9. Mackall CL, Stein D, Fleisher TA, et al. Prolonged CD4 depletion after sequential autologous peripheral blood progenitor cell infusions in children and young adults. Blood. 2000;96:754-762.
10. Blattman JN, Greenberg PD. Cancer immunotherapy: a treatment for the masses. Science. 2004;305:200-205.
11. Kushner B, Kramer K, Cheung NK. Phase II trial of the anti-G(D2) monocolonal antibody 3F8 and granulocyte-macrophage colony-stimulating factor for neuroblastoma [abstract]. J Clin Oncol. 2001;19:4189-4194.
12. Keilholz U, Weber J, Finke JH, et al. Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy. J Immunother (1997). 2002;25:97-138.
13. + T cells in the priming and effector/memory phases of adoptive immunotherapy. J Immunol. 2000;165:4246-4253.
14. + cytotoxic T lymphocytes against MHC class II-negative mouse hepatocellular carcinoma induced by dendritic cell vaccine and interleukin-12. Immunology. 2005;115:451-461.
15. Perez-Diez A, Joncker NT, Choi K, et al. CD4 cells can be more efficient at tumor rejection than CD8 cells. Blood. 2007;109:5346-5354.
16. Chu Y, Xia M, Lin Y, et al. TH2-dominated antitumor immunity induced by DNA immunization with the genes coding for a basal core peptide PDTRP and GM-CSF. Cancer Gene Ther. 2006;13:510-519.
17. Rousseau RF, Biagi E, Dutour A, et al. Immunotherapy of high-risk acute leukemia with a recipient (autologous) vaccine expressing transgenic human CD40L and IL-2 after chemotherapy and allogeneic stem cell transplantation. Blood. 2006;107:1332-1341.
18. Rousseau RF, Haight AE, Hirschmann-Jax C, et al. Local and systemic effects of an allogeneic tumor cell vaccine combining transgenic human lymphotactin with interleukin-2 in patients with advanced or refractory neuroblastoma. Blood. 2003;101:1718-1726.
19. Russell HV, Strother D, Mei Z, et al. Phase I trial of vaccination with autologous neuroblastoma tumor cells genetically modified to secrete IL-2 and lymphotactin. J Immunother (1997). 2007;30:227-233.
20. Macdonald D, Gordon AA, Kajitani H, et al. Interleukin-2 treatment-associated eosinophilia is mediated by interleukin-5 production. Br J Haematol. 1990;76:168-173.
21. Cormier SA, Taranova AG, Bedient C, et al. Pivotal advance: eosinophil infiltration of solid tumors is an early and persistent inflammatory host response. J Leukoc Biol. 2006;79:1131-1139.
22. Samoszuk M. Eosinophils and human cancer. Histol Histopathol. 1997;12:807-812.
23. Woodson EM, Chianese-Bullock KA, Wiernasz CJ, et al. Assessment of the toxicities of systemic low-dose interleukin-2 administered in conjunction with a melanoma peptide vaccine. J Immunother. 2004;27:380-388.
24. Sosman JA, Bartemes K, Offord KP, et al. Evidence for eosinophil activation in cancer patients receiving recombinant interleukin-4: effects of interleukin-4 alone and following interleukin-2 administration. Clin Cancer Res. 1995;1:805-812.
25. Hartman ZC, Appledorn DM, Amalfitano A. Adenovirus vector induced innate immune responses: impact upon efficacy and toxicity in gene therapy and vaccine applications. Virus Res. 2008;132:1-14.
26. Sakamoto N, Tsuji K, Muul LM, et al. Bovine apolipoprotein B-100 is a dominant immunogen in therapeutic cell populations cultured in fetal calf serum in mice and humans. Blood. 2007;110:501-508.